GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » Cyclically Adjusted FCF per Share

Aspira Womens Health (FRA:CUL) Cyclically Adjusted FCF per Share : €-3.93 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Aspira Womens Health Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aspira Womens Health's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.346. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-3.93 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 17.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 28.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Aspira Womens Health was 41.70% per year. The lowest was 12.80% per year. And the median was 20.95% per year.

As of today (2024-05-24), Aspira Womens Health's current stock price is €2.02. Aspira Womens Health's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-3.93. Aspira Womens Health's Cyclically Adjusted Price-to-FCF of today is .


Aspira Womens Health Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Aspira Womens Health's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Cyclically Adjusted FCF per Share Chart

Aspira Womens Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.71 -4.88 -4.71 -4.39 -4.34

Aspira Womens Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.90 -5.65 -3.44 -4.34 -3.93

Competitive Comparison of Aspira Womens Health's Cyclically Adjusted FCF per Share

For the Diagnostics & Research subindustry, Aspira Womens Health's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Cyclically Adjusted Price-to-FCF falls into.



Aspira Womens Health Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aspira Womens Health's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.346/131.7762*131.7762
=-0.346

Current CPI (Mar. 2024) = 131.7762.

Aspira Womens Health Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1.174 100.560 -1.538
201409 -1.781 100.428 -2.337
201412 -1.403 99.070 -1.866
201503 -1.467 99.621 -1.941
201506 -1.568 100.684 -2.052
201509 -1.168 100.392 -1.533
201512 -1.433 99.792 -1.892
201603 -1.441 100.470 -1.890
201606 -1.007 101.688 -1.305
201609 -0.750 101.861 -0.970
201612 -0.757 101.863 -0.979
201703 -0.634 102.862 -0.812
201706 -0.425 103.349 -0.542
201709 -0.394 104.136 -0.499
201712 -0.455 104.011 -0.576
201803 -0.483 105.290 -0.605
201806 -0.450 106.317 -0.558
201809 -0.396 106.507 -0.490
201812 -0.411 105.998 -0.511
201903 -0.555 107.251 -0.682
201906 -0.623 108.070 -0.760
201909 -0.488 108.329 -0.594
201912 -0.400 108.420 -0.486
202003 -0.492 108.902 -0.595
202006 -0.476 108.767 -0.577
202009 -0.396 109.815 -0.475
202012 -0.589 109.897 -0.706
202103 -0.614 111.754 -0.724
202106 -0.732 114.631 -0.841
202109 -0.912 115.734 -1.038
202112 -0.909 117.630 -1.018
202203 -1.245 121.301 -1.353
202206 -0.800 125.017 -0.843
202209 -0.979 125.227 -1.030
202212 -0.813 125.222 -0.856
202303 -0.642 127.348 -0.664
202306 -0.376 128.729 -0.385
202309 -0.318 129.860 -0.323
202312 -0.305 129.419 -0.311
202403 -0.346 131.776 -0.346

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Aspira Womens Health  (FRA:CUL) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aspira Womens Health Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (FRA:CUL) Business Description

Traded in Other Exchanges
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines